Synaffix BV

Formed in 2010, Synaffix is a Netherlands-based biotechnology company exclusively focused on continued advancement of a best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, the vision of Synaffix is to become the preferred partner in the development of these complex biological therapeutics and realize its ambition - connect to cure.

http://www.synaffix.com/

Team Member
more about
Hakan Goker
Latest News Entry
2017/05/16
Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States

exclusively focused on the development of industry-leading antibody-drug conjugate
(ADC) technology platforms, today announced that a key patent covering its HydraSpace™
spacer technology has been granted by the United States Patent and Trademark Office
(US 9,636,421 B2).

all portfolio news